,address1,address2,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,totalDebt,quickRatio,currentRatio,returnOnAssets,returnOnEquity,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,2222 Ponce de Leon Boulevard,Floor 3,Coral Gables,FL,33134,United States,786 629 1376,https://www.relmada.com,Biotechnology,Healthcare,"Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.",14,"{'maxAge': 1, 'name': 'Dr. Sergio  Traversa M.B.A., MBA, Pharm.D., PharmD', 'age': 62, 'title': 'CEO & Director', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 719041, 'exercisedValue': 0, 'unexercisedValue': 34490}",4,9,9,4,8,1693526400,1672444800,86400,4,3.31,3.31,3.08,3.32,3.31,3.31,3.08,3.32,0.0,0.0778,-1.1839081,145033,145033,159324,102570,102570,2.93,3.3,900,1300,93006528,1.81,38.68,2.9957,3.118825,0.0,0.0,USD,-25522554,0.0,22532865,30099200,617735,849914,1690761600,1693440000,0.020499999,0.07819,0.60687,6.92,0.0209,3.699,0.8353609,1672444800,1703980800,1688083200,-128987600,-4.0,-2.61,1:4,1569801600,NMS,EQUITY,RLMD,RLMD,"Relmada Therapeutics, Inc.","Relmada Therapeutics, Inc.",1403271000,America/New_York,EDT,-14400000,3.09,25.0,3.0,10.31,6.63,2.4,buy,4,118529088,3.938,0,11.075,11.4,-0.48703,-0.83707,-47680408,-92524096,0.0,0.0,0.0,USD,
1,2222 Ponce de Leon Boulevard,Floor 3,Coral Gables,FL,33134,United States,786 629 1376,https://www.relmada.com,Biotechnology,Healthcare,"Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.",14,"{'maxAge': 1, 'name': 'Mr. Maged S. Shenouda M.B.A., MBA, R.Ph, R.Ph.', 'age': 58, 'title': 'Chief Financial Officer', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 450353, 'exercisedValue': 0, 'unexercisedValue': 25070}",4,9,9,4,8,1693526400,1672444800,86400,4,3.31,3.31,3.08,3.32,3.31,3.31,3.08,3.32,0.0,0.0778,-1.1839081,145033,145033,159324,102570,102570,2.93,3.3,900,1300,93006528,1.81,38.68,2.9957,3.118825,0.0,0.0,USD,-25522554,0.0,22532865,30099200,617735,849914,1690761600,1693440000,0.020499999,0.07819,0.60687,6.92,0.0209,3.699,0.8353609,1672444800,1703980800,1688083200,-128987600,-4.0,-2.61,1:4,1569801600,NMS,EQUITY,RLMD,RLMD,"Relmada Therapeutics, Inc.","Relmada Therapeutics, Inc.",1403271000,America/New_York,EDT,-14400000,3.09,25.0,3.0,10.31,6.63,2.4,buy,4,118529088,3.938,0,11.075,11.4,-0.48703,-0.83707,-47680408,-92524096,0.0,0.0,0.0,USD,
2,2222 Ponce de Leon Boulevard,Floor 3,Coral Gables,FL,33134,United States,786 629 1376,https://www.relmada.com,Biotechnology,Healthcare,"Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.",14,"{'maxAge': 1, 'name': 'Mr. Charles S. Ence CPA, M.B.A.', 'age': 57, 'title': 'Chief Accounting & Compliance Officer', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 568679, 'exercisedValue': 0, 'unexercisedValue': 2203}",4,9,9,4,8,1693526400,1672444800,86400,4,3.31,3.31,3.08,3.32,3.31,3.31,3.08,3.32,0.0,0.0778,-1.1839081,145033,145033,159324,102570,102570,2.93,3.3,900,1300,93006528,1.81,38.68,2.9957,3.118825,0.0,0.0,USD,-25522554,0.0,22532865,30099200,617735,849914,1690761600,1693440000,0.020499999,0.07819,0.60687,6.92,0.0209,3.699,0.8353609,1672444800,1703980800,1688083200,-128987600,-4.0,-2.61,1:4,1569801600,NMS,EQUITY,RLMD,RLMD,"Relmada Therapeutics, Inc.","Relmada Therapeutics, Inc.",1403271000,America/New_York,EDT,-14400000,3.09,25.0,3.0,10.31,6.63,2.4,buy,4,118529088,3.938,0,11.075,11.4,-0.48703,-0.83707,-47680408,-92524096,0.0,0.0,0.0,USD,
3,2222 Ponce de Leon Boulevard,Floor 3,Coral Gables,FL,33134,United States,786 629 1376,https://www.relmada.com,Biotechnology,Healthcare,"Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.",14,"{'maxAge': 1, 'name': 'Dr. Paolo  Manfredi M.D., Ph.D.', 'age': 60, 'title': 'Chief Scientific Officer', 'yearBorn': 1962, 'exercisedValue': 0, 'unexercisedValue': 0}",4,9,9,4,8,1693526400,1672444800,86400,4,3.31,3.31,3.08,3.32,3.31,3.31,3.08,3.32,0.0,0.0778,-1.1839081,145033,145033,159324,102570,102570,2.93,3.3,900,1300,93006528,1.81,38.68,2.9957,3.118825,0.0,0.0,USD,-25522554,0.0,22532865,30099200,617735,849914,1690761600,1693440000,0.020499999,0.07819,0.60687,6.92,0.0209,3.699,0.8353609,1672444800,1703980800,1688083200,-128987600,-4.0,-2.61,1:4,1569801600,NMS,EQUITY,RLMD,RLMD,"Relmada Therapeutics, Inc.","Relmada Therapeutics, Inc.",1403271000,America/New_York,EDT,-14400000,3.09,25.0,3.0,10.31,6.63,2.4,buy,4,118529088,3.938,0,11.075,11.4,-0.48703,-0.83707,-47680408,-92524096,0.0,0.0,0.0,USD,
4,2222 Ponce de Leon Boulevard,Floor 3,Coral Gables,FL,33134,United States,786 629 1376,https://www.relmada.com,Biotechnology,Healthcare,"Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.",14,"{'maxAge': 1, 'name': 'Ms. Gina  DiGuglielmo', 'title': 'VP & Head of Clinical Operations', 'exercisedValue': 0, 'unexercisedValue': 0}",4,9,9,4,8,1693526400,1672444800,86400,4,3.31,3.31,3.08,3.32,3.31,3.31,3.08,3.32,0.0,0.0778,-1.1839081,145033,145033,159324,102570,102570,2.93,3.3,900,1300,93006528,1.81,38.68,2.9957,3.118825,0.0,0.0,USD,-25522554,0.0,22532865,30099200,617735,849914,1690761600,1693440000,0.020499999,0.07819,0.60687,6.92,0.0209,3.699,0.8353609,1672444800,1703980800,1688083200,-128987600,-4.0,-2.61,1:4,1569801600,NMS,EQUITY,RLMD,RLMD,"Relmada Therapeutics, Inc.","Relmada Therapeutics, Inc.",1403271000,America/New_York,EDT,-14400000,3.09,25.0,3.0,10.31,6.63,2.4,buy,4,118529088,3.938,0,11.075,11.4,-0.48703,-0.83707,-47680408,-92524096,0.0,0.0,0.0,USD,
5,2222 Ponce de Leon Boulevard,Floor 3,Coral Gables,FL,33134,United States,786 629 1376,https://www.relmada.com,Biotechnology,Healthcare,"Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.",14,"{'maxAge': 1, 'name': 'Dr. Marco  Pappagallo M.D.', 'age': 63, 'title': 'Chief Clinical Officer', 'yearBorn': 1959, 'exercisedValue': 0, 'unexercisedValue': 0}",4,9,9,4,8,1693526400,1672444800,86400,4,3.31,3.31,3.08,3.32,3.31,3.31,3.08,3.32,0.0,0.0778,-1.1839081,145033,145033,159324,102570,102570,2.93,3.3,900,1300,93006528,1.81,38.68,2.9957,3.118825,0.0,0.0,USD,-25522554,0.0,22532865,30099200,617735,849914,1690761600,1693440000,0.020499999,0.07819,0.60687,6.92,0.0209,3.699,0.8353609,1672444800,1703980800,1688083200,-128987600,-4.0,-2.61,1:4,1569801600,NMS,EQUITY,RLMD,RLMD,"Relmada Therapeutics, Inc.","Relmada Therapeutics, Inc.",1403271000,America/New_York,EDT,-14400000,3.09,25.0,3.0,10.31,6.63,2.4,buy,4,118529088,3.938,0,11.075,11.4,-0.48703,-0.83707,-47680408,-92524096,0.0,0.0,0.0,USD,
6,2222 Ponce de Leon Boulevard,Floor 3,Coral Gables,FL,33134,United States,786 629 1376,https://www.relmada.com,Biotechnology,Healthcare,"Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.",14,"{'maxAge': 1, 'name': 'Mr. John  Hixon', 'title': 'Head of Commercial', 'exercisedValue': 0, 'unexercisedValue': 0}",4,9,9,4,8,1693526400,1672444800,86400,4,3.31,3.31,3.08,3.32,3.31,3.31,3.08,3.32,0.0,0.0778,-1.1839081,145033,145033,159324,102570,102570,2.93,3.3,900,1300,93006528,1.81,38.68,2.9957,3.118825,0.0,0.0,USD,-25522554,0.0,22532865,30099200,617735,849914,1690761600,1693440000,0.020499999,0.07819,0.60687,6.92,0.0209,3.699,0.8353609,1672444800,1703980800,1688083200,-128987600,-4.0,-2.61,1:4,1569801600,NMS,EQUITY,RLMD,RLMD,"Relmada Therapeutics, Inc.","Relmada Therapeutics, Inc.",1403271000,America/New_York,EDT,-14400000,3.09,25.0,3.0,10.31,6.63,2.4,buy,4,118529088,3.938,0,11.075,11.4,-0.48703,-0.83707,-47680408,-92524096,0.0,0.0,0.0,USD,
7,2222 Ponce de Leon Boulevard,Floor 3,Coral Gables,FL,33134,United States,786 629 1376,https://www.relmada.com,Biotechnology,Healthcare,"Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.",14,"{'maxAge': 1, 'name': ""Dr. Cedric  O'Gorman M.B.A., M.D., MBA"", 'age': 46, 'title': 'Chief Medical Officer', 'yearBorn': 1976, 'exercisedValue': 0, 'unexercisedValue': 0}",4,9,9,4,8,1693526400,1672444800,86400,4,3.31,3.31,3.08,3.32,3.31,3.31,3.08,3.32,0.0,0.0778,-1.1839081,145033,145033,159324,102570,102570,2.93,3.3,900,1300,93006528,1.81,38.68,2.9957,3.118825,0.0,0.0,USD,-25522554,0.0,22532865,30099200,617735,849914,1690761600,1693440000,0.020499999,0.07819,0.60687,6.92,0.0209,3.699,0.8353609,1672444800,1703980800,1688083200,-128987600,-4.0,-2.61,1:4,1569801600,NMS,EQUITY,RLMD,RLMD,"Relmada Therapeutics, Inc.","Relmada Therapeutics, Inc.",1403271000,America/New_York,EDT,-14400000,3.09,25.0,3.0,10.31,6.63,2.4,buy,4,118529088,3.938,0,11.075,11.4,-0.48703,-0.83707,-47680408,-92524096,0.0,0.0,0.0,USD,
8,2222 Ponce de Leon Boulevard,Floor 3,Coral Gables,FL,33134,United States,786 629 1376,https://www.relmada.com,Biotechnology,Healthcare,"Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.",14,"{'maxAge': 1, 'name': 'Dr. Richard M. Mangano', 'age': 72, 'title': 'Consultant', 'yearBorn': 1950, 'fiscalYear': 2018, 'exercisedValue': 0, 'unexercisedValue': 0}",4,9,9,4,8,1693526400,1672444800,86400,4,3.31,3.31,3.08,3.32,3.31,3.31,3.08,3.32,0.0,0.0778,-1.1839081,145033,145033,159324,102570,102570,2.93,3.3,900,1300,93006528,1.81,38.68,2.9957,3.118825,0.0,0.0,USD,-25522554,0.0,22532865,30099200,617735,849914,1690761600,1693440000,0.020499999,0.07819,0.60687,6.92,0.0209,3.699,0.8353609,1672444800,1703980800,1688083200,-128987600,-4.0,-2.61,1:4,1569801600,NMS,EQUITY,RLMD,RLMD,"Relmada Therapeutics, Inc.","Relmada Therapeutics, Inc.",1403271000,America/New_York,EDT,-14400000,3.09,25.0,3.0,10.31,6.63,2.4,buy,4,118529088,3.938,0,11.075,11.4,-0.48703,-0.83707,-47680408,-92524096,0.0,0.0,0.0,USD,
